article · Benha Medical Journal
Purpose: We aimed to assess the rule of plasma miR-30b- 5P as a biomarker for early diagnosis of breast cancer (BrC).Patients and Methods: This case control study was conducted on 50 participants, females, newly diagnosed with breast cancer before receiving any treatment. Subjects were categorized into two groups: Group I (patient group): 35 adults, their age was (53.6 ± 12.20) years, are newly diagnosed BrC before any treatment and Group II (control group): 15 subjects, their age was (47.7 ± 9.59) years, apparently healthy matching age and sex with patients.Results: There is statistically significant difference regarding presence of lesions by Mammogram when compare cases with control (p < .001). And there is a significant elevation in the expression of miR - 30 b - 5p when comparing cases with control group (p < .001).Conclusion: Plasma miR-30b-5P can be used as a biomarker for early diagnosis of BrC.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/bmfj.2024.294366.2091
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.